Micromet Purchased by Amgen for Anti-Leukemia Drug

by Kathy Jones on  January 27, 2012 at 8:43 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

The German-American cancer research firm Micromet is being taken over by biotech giant Amgen, thus giving it access to Micromet's promising leukemia therapy.
 Micromet Purchased by Amgen for Anti-Leukemia Drug
Micromet Purchased by Amgen for Anti-Leukemia Drug

Amgen said it would pay $1.16 billion for Micromet, founded by a team of German scientists to tap the potential of T-cell therapies to fight cancer.

The company, based in Rockville, Maryland, has developed blinatumomab, a T-cell based treatment for acute lymphoblastic leukemia and possibly non-Hodgkin's lymphoma that is still undergoing testing.

"Blinatumomab will serve as an important complement to our oncology pipeline and is representative of our corporate strategy, which is focused on developing and successfully commercializing therapeutics to treat patients with grievous illness," Amgen chief executive Kevin Sharer said in a statement.

The deal is worth $11 a share to Micromet shareholders. The Nasdaq-listed company's price jumped 31.9 percent to $10.92 after the announcement.

California-based Amgen's share price fell 1.4 percent to $68.25.

Source: AFP

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Signature Drug Toxicity Top Ten Selling Drugs 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive